Multiple myeloma therapy: emerging trends and challenges
Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
Synthetic antigen-conjugated dna systems for antibody detection and characterization
Antibodies are among the most relevant biomolecular targets for diagnostic and clinical
applications. In this Perspective, we provide a critical overview of recent research efforts …
applications. In this Perspective, we provide a critical overview of recent research efforts …
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
B-cell maturation antigen (BCMA) is a novel target for T-cell immunotherapy in multiple
myeloma (MM) including bispecific antibody (bsAb), antibody drug conjugates, and chimeric …
myeloma (MM) including bispecific antibody (bsAb), antibody drug conjugates, and chimeric …
Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma
LR Hammons, A Szabo, A Janardan… - JAMA network …, 2022 - jamanetwork.com
Bispecific antibodies (bsAb) targeting novel antigens are a promising class of therapeutics
for relapsed refractory multiple myeloma (RRMM). 1, 2 Although hypogammaglobulinemia is …
for relapsed refractory multiple myeloma (RRMM). 1, 2 Although hypogammaglobulinemia is …
Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety
M Offidani, L Corvatta, S Morè… - Drug design, development …, 2021 - Taylor & Francis
Despite the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs),
and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly …
and, more recently, monoclonal antibodies (mAbs), in the chemotherapy regimens for newly …
[HTML][HTML] Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
M Barreca, N Lang, C Tarantelli, F Spriano… - … of Targeted Anti …, 2022 - ncbi.nlm.nih.gov
Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies
treatment, designed to provide superior efficacy and specific targeting of tumor cells …
treatment, designed to provide superior efficacy and specific targeting of tumor cells …
Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma
Simple Summary Multiple myeloma is the second most common hematological malignancy
and while patients can have long responses to therapy, most patients will eventually …
and while patients can have long responses to therapy, most patients will eventually …
[HTML][HTML] Novel immunotherapies in multiple myeloma–chances and challenges
L Rasche, R Wäsch, M Munder, H Goldschmidt… - …, 2021 - ncbi.nlm.nih.gov
In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-
cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple …
cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple …
Innovation in BCMA CAR-T therapy: Building beyond the Model T
R Banerjee, SS Lee, AJ Cowan - Frontiers in Oncology, 2022 - frontiersin.org
Autologous chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …
antigen (BCMA) have revolutionized the field of multiple myeloma in the same way that the …
Targeting CD38 for acute leukemia
X Zhong, H Ma - Frontiers in Oncology, 2022 - frontiersin.org
Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients
hasn't improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new …
hasn't improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new …